ArticleInternational journal of clinical oncology2026
Real-world perioperative systemic treatment patterns and postoperative mortality in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy in Japan: WAKKA-UTUC study.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo characterize the longitudinal changes in perioperative systemic treatment patterns and postoperative mortality among Japanese patients with stage II-IV upper tract urothelial carcinoma (UTUC) who underwent radical nephroureterectomy (RNU).
methodsThis retrospective observational study used a nationwide Japanese database to evaluate neoadjuvant chemotherapy (NAC) and adjuvant therapy (AT) before and after RNU. Treatment patterns, specific regimens, and 30- and 90-day postoperative mortality were analyzed descriptively across three periods: 2013-2017, 2018-2021, and 2022-2024.
resultsAmong 6,165 patients included in the study, the use of AT without prior NAC increased from 25.7% in 2013-2017 to 30.0% in 2022-2024, and the proportion of patients who received any NAC increased from 9.8% to 17.1%, respectively. By 2022-2024, gemcitabine plus carboplatin emerged as the most widely used regimen for NAC and AT (6.5% and 15.2% of the overall study population during this period [n = 1,482], respectively). Adjuvant nivolumab was administered to 142 patients (9.6% of all patients undergoing RNU in 2022-2024), but most (n = 84) had not received prior NAC. Postoperative mortality remained stable across the study periods (30-day mortality: 0.0%-0.5%; 90-day mortality: 0.3%-2.0%), with no increase in mortality among patients who received NAC.
conclusionsThe use of perioperative systemic therapy for UTUC in Japan increased over the study period, with growing adoption of NAC, AT, and adjuvant nivolumab. Postoperative mortality remained stable, showing no notable association with NAC.
Indexed as
Identifiers
42762421What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.